{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T12:24:52Z","timestamp":1791289492754,"version":"4.3.0"},"reference-count":118,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2018,7,16]],"date-time":"2018-07-16T00:00:00Z","timestamp":1531699200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Nephrol"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1038\/s41581-018-0035-1","type":"journal-article","created":{"date-parts":[[2018,7,16]],"date-time":"2018-07-16T13:43:25Z","timestamp":1531748605000},"page":"571-588","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":98,"title":["Cardiorenal complications of immune checkpoint inhibitors"],"prefix":"10.1038","volume":"14","author":[{"given":"Krishna","family":"Sury","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark A.","family":"Perazella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anushree C.","family":"Shirali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,7,16]]},"reference":[{"key":"35_CR1","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.immuni.2004.07.017","volume":"21","author":"GP Dunn","year":"2004","unstructured":"Dunn, G. P., Old, L. J. & Schreiber, R. D. The immunobiology of cancer immunosurveillance and immunoediting. Immunity 21, 137\u2013148 (2004).","journal-title":"Immunity"},{"key":"35_CR2","doi-asserted-by":"publisher","first-page":"7466","DOI":"10.4049\/jimmunol.179.11.7466","volume":"179","author":"J Menke","year":"2007","unstructured":"Menke, J. et al. Programmed death 1 ligand (PD-L) 1 and PD-L2 limit autoimmune kidney disease: distinct roles. J. Immunol. 179, 7466\u20137477 (2007).","journal-title":"J. Immunol."},{"key":"35_CR3","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1136\/bmj.1.5022.779","volume":"1","author":"M Burnet","year":"1957","unstructured":"Burnet, M. Cancer; a biological approach. I. The processes of control. Br. Med. J. 1, 779\u2013786 (1957).","journal-title":"Br. Med. J."},{"key":"35_CR4","first-page":"329","volume":"55","author":"L Thomas","year":"1982","unstructured":"Thomas, L. On immunosurveillance in human cancer. Yale J. Biol. Med. 55, 329\u2013333 (1982).","journal-title":"Yale J. Biol. Med."},{"key":"35_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000386035","volume":"13","author":"FM Burnet","year":"1970","unstructured":"Burnet, F. M. The concept of immunological surveillance. Prog. Exp. Tumor Res. 13, 1\u201327 (1970).","journal-title":"Prog. Exp. Tumor Res."},{"key":"35_CR6","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1126\/science.183.4124.534","volume":"183","author":"O Stutman","year":"1974","unstructured":"Stutman, O. Tumor development after 3-methylcholanthrene in immunologically deficient athymic-nude mice. Science 183, 534\u2013536 (1974).","journal-title":"Science"},{"key":"35_CR7","doi-asserted-by":"publisher","first-page":"7556","DOI":"10.1073\/pnas.95.13.7556","volume":"95","author":"DH Kaplan","year":"1998","unstructured":"Kaplan, D. H. et al. Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proc. Natl Acad. Sci. USA 95, 7556\u20137561 (1998).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"35_CR8","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1084\/jem.184.5.1781","volume":"184","author":"ME Broek van den","year":"1996","unstructured":"van den Broek, M. E. et al. Decreased tumor surveillance in perforin-deficient mice. J. Exp. Med. 184, 1781\u20131790 (1996).","journal-title":"J. Exp. Med."},{"key":"35_CR9","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1001\/jama.2011.1592","volume":"306","author":"EA Engels","year":"2011","unstructured":"Engels, E. A. et al. Spectrum of cancer risk among US solid organ transplant recipients. JAMA 306, 1891\u20131901 (2011).","journal-title":"JAMA"},{"key":"35_CR10","doi-asserted-by":"publisher","first-page":"2300","DOI":"10.1002\/cncr.28043","volume":"119","author":"EC Hall","year":"2013","unstructured":"Hall, E. C., Pfeiffer, R. M., Segev, D. L. & Engels, E. A. Cumulative incidence of cancer after solid organ transplantation. Cancer 119, 2300\u20132308 (2013).","journal-title":"Cancer"},{"key":"35_CR11","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1097\/00007890-199809150-00020","volume":"66","author":"MG Suranyi","year":"1998","unstructured":"Suranyi, M. G. et al. Advanced donor-origin melanoma in a renal transplant recipient: immunotherapy, cure, and retransplantation. Transplantation 66, 655\u2013661 (1998).","journal-title":"Transplantation"},{"key":"35_CR12","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1056\/NEJM200302063480620","volume":"348","author":"RM MacKie","year":"2003","unstructured":"MacKie, R. M., Reid, R. & Junor, B. Fatal melanoma transferred in a donated kidney 16 years after melanoma surgery. N. Engl. J. Med. 348, 567\u2013568 (2003).","journal-title":"N. Engl. J. Med."},{"key":"35_CR13","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1126\/science.1203486","volume":"331","author":"RD Schreiber","year":"2011","unstructured":"Schreiber, R. D., Old, L. J. & Smyth, M. J. Cancer immunoediting: integrating immunity\u2019s roles in cancer suppression and promotion. Science 331, 1565\u20131570 (2011).","journal-title":"Science"},{"key":"35_CR14","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.currproblcancer.2016.12.004","volume":"41","author":"N Murakami","year":"2017","unstructured":"Murakami, N., Motwani, S. & Riella, L. V. Renal complications of immune checkpoint blockade. Curr. Problems Cancer 41, 100\u2013110 (2017).","journal-title":"Curr. Problems Cancer"},{"key":"35_CR15","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1053\/j.seminoncol.2010.09.005","volume":"37","author":"J Weber","year":"2010","unstructured":"Weber, J. Immune checkpoint proteins: a new therapeutic paradigm for cancer \u2014 preclinical background: CTLA-4 and PD-1 blockade. Semin. Oncol. 37, 430\u2013439 (2010).","journal-title":"Semin. Oncol."},{"key":"35_CR16","doi-asserted-by":"publisher","first-page":"2729","DOI":"10.4049\/jimmunol.168.6.2729","volume":"168","author":"LJ Appleman","year":"2002","unstructured":"Appleman, L. J., van Puijenbroek, A. A., Shu, K. M., Nadler, L. M. & Boussiotis, V. A. CD28 costimulation mediates down-regulation of p27kip1 and cell cycle progression by activation of the PI3K\/PKB signaling pathway in primary human T cells. J. Immunol. 168, 2729\u20132736 (2002).","journal-title":"J. Immunol."},{"key":"35_CR17","doi-asserted-by":"crossref","first-page":"3788","DOI":"10.1093\/jimmunol\/185.7.3788","volume":"185","author":"LH Boise","year":"2010","unstructured":"Boise, L. H. et al. CD28 costimulation can promote T cell survival by enhancing the expression of Bcl-xL. Immunity. 1995. 3, 87\u201398. J. Immunol. 185, 3788\u20133799 (2010).","journal-title":"J. Immunol."},{"key":"35_CR18","doi-asserted-by":"publisher","first-page":"9543","DOI":"10.1128\/MCB.25.21.9543-9553.2005","volume":"25","author":"RV Parry","year":"2005","unstructured":"Parry, R. V. et al. CTLA-4 and PD-1 receptors inhibit T cell activation by distinct mechanisms. Mol. Cell. Biol. 25, 9543\u20139553 (2005).","journal-title":"Mol. Cell. Biol."},{"key":"35_CR19","doi-asserted-by":"publisher","first-page":"2572","DOI":"10.1002\/eji.1830231029","volume":"23","author":"SG Ward","year":"1993","unstructured":"Ward, S. G., Westwick, J., Hall, N. D. & Sansom, D. M. Ligation of CD28 receptor by B7 induces formation of D-3 phosphoinositides in T lymphocytes independently of T cell receptor\/CD3 activation. Eur. J. Immunol. 23, 2572\u20132577 (1993).","journal-title":"Eur. J. Immunol."},{"key":"35_CR20","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1056\/NEJMra1514296","volume":"375","author":"VA Boussiotis","year":"2016","unstructured":"Boussiotis, V. A. Molecular and biochemical aspects of the PD-1 checkpoint pathway. N. Engl. J. Med. 375, 1767\u20131778 (2016).","journal-title":"N. Engl. J. Med."},{"key":"35_CR21","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1111\/j.1600-065X.2010.00923.x","volume":"236","author":"LM Francisco","year":"2010","unstructured":"Francisco, L. M., Sage, P. T. & Sharpe, A. H. The PD-1 pathway in tolerance and autoimmunity. Immunol. Rev. 236, 219\u2013242 (2010).","journal-title":"Immunol. Rev."},{"key":"35_CR22","doi-asserted-by":"publisher","first-page":"2575","DOI":"10.1111\/j.1600-6143.2012.04224.x","volume":"12","author":"LV Riella","year":"2012","unstructured":"Riella, L. V., Paterson, A. M., Sharpe, A. H. & Chandraker, A. Role of the PD-1 pathway in the immune response. Am. J. Transplant. 12, 2575\u20132587 (2012).","journal-title":"Am. J. Transplant."},{"key":"35_CR23","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/nri3790","volume":"15","author":"LT Nguyen","year":"2015","unstructured":"Nguyen, L. T. & Ohashi, P. S. Clinical blockade of PD1 and LAG3 \u2014 potential mechanisms of action. Nat. Rev. Immunol. 15, 45\u201356 (2015).","journal-title":"Nat. Rev. Immunol."},{"key":"35_CR24","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1146\/annurev.immunol.26.021607.090331","volume":"26","author":"ME Keir","year":"2008","unstructured":"Keir, M. E., Butte, M. J., Freeman, G. J. & Sharpe, A. H. PD-1 and its ligands in tolerance and immunity. Annu. Rev. Immunol. 26, 677\u2013704 (2008).","journal-title":"Annu. Rev. Immunol."},{"key":"35_CR25","doi-asserted-by":"publisher","first-page":"13866","DOI":"10.1073\/pnas.231486598","volume":"98","author":"T Okazaki","year":"2001","unstructured":"Okazaki, T., Maeda, A., Nishimura, H., Kurosaki, T. & Honjo, T. PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine. Proc. Natl Acad. Sci. USA 98, 13866\u201313871 (2001).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"35_CR26","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.febslet.2004.07.083","volume":"574","author":"KA Sheppard","year":"2004","unstructured":"Sheppard, K. A. et al. PD-1 inhibits T cell receptor induced phosphorylation of the ZAP70\/CD3zeta signalosome and downstream signaling to PKCtheta. FEBS Lett. 574, 37\u201341 (2004).","journal-title":"FEBS Lett."},{"key":"35_CR27","doi-asserted-by":"publisher","first-page":"945","DOI":"10.4049\/jimmunol.173.2.945","volume":"173","author":"JM Chemnitz","year":"2004","unstructured":"Chemnitz, J. M., Parry, R. V., Nichols, K. E., June, C. H. & Riley, J. L. SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation. J. Immunol. 173, 945\u2013954 (2004).","journal-title":"J. Immunol."},{"key":"35_CR28","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/S1074-7613(00)80480-X","volume":"4","author":"PS Linsley","year":"1996","unstructured":"Linsley, P. S. et al. Intracellular trafficking of CTLA-4 and focal localization towards sites of TCR engagement. Immunity 4, 535\u2013543 (1996).","journal-title":"Immunity"},{"key":"35_CR29","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1046\/j.1365-2567.1999.00888.x","volume":"98","author":"K Vandenborre","year":"1999","unstructured":"Vandenborre, K. et al. Interaction of CTLA-4 (CD152) with CD80 or CD86 inhibits human T cell activation. Immunology 98, 413\u2013421 (1999).","journal-title":"Immunology"},{"key":"35_CR30","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1084\/jem.188.1.205","volume":"188","author":"F Fallarino","year":"1998","unstructured":"Fallarino, F., Fields, P. E. & Gajewski, T. F. B7-1 engagement of cytotoxic T lymphocyte antigen 4 inhibits T cell activation in the absence of CD28. J. Exp. Med. 188, 205\u2013210 (1998).","journal-title":"J. Exp. Med."},{"key":"35_CR31","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.imlet.2007.09.004","volume":"115","author":"J Downey","year":"2008","unstructured":"Downey, J. TCR\/CD3 mediated stop-signal is decoupled in T cells from Ctla4 deficient mice. Immunol. Lett. 115, 70\u201372 (2008).","journal-title":"Immunol. Lett."},{"key":"35_CR32","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1002\/eji.200737423","volume":"38","author":"H Schneider","year":"2008","unstructured":"Schneider, H., Smith, X., Liu, H., Bismuth, G. & Rudd, C. E. CTLA-4 disrupts ZAP70 microcluster formation with reduced T cell\/APC dwell times and calcium mobilization. Eur. J. Immunol. 38, 40\u201347 (2008).","journal-title":"Eur. J. Immunol."},{"key":"35_CR33","doi-asserted-by":"publisher","first-page":"2533","DOI":"10.1084\/jem.183.6.2533","volume":"183","author":"MF Krummel","year":"1996","unstructured":"Krummel, M. F. & Allison, J. P. CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells. J. Exp. Med. 183, 2533\u20132540 (1996).","journal-title":"J. Exp. Med."},{"key":"35_CR34","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1111\/j.1600-065X.2009.00770.x","volume":"229","author":"CE Rudd","year":"2009","unstructured":"Rudd, C. E., Taylor, A. & Schneider, H. CD28 and CTLA-4 coreceptor expression and signal transduction. Immunol. Rev. 229, 12\u201326 (2009).","journal-title":"Immunol. Rev."},{"key":"35_CR35","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1126\/science.1160062","volume":"322","author":"K Wing","year":"2008","unstructured":"Wing, K. et al. CTLA-4 control over Foxp3+ regulatory T cell function. Science 322, 271\u2013275 (2008).","journal-title":"Science"},{"key":"35_CR36","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/S1074-7613(00)80284-8","volume":"6","author":"VL Perez","year":"1997","unstructured":"Perez, V. L. et al. Induction of peripheral T cell tolerance in vivo requires CTLA-4 engagement. Immunity 6, 411\u2013417 (1997).","journal-title":"Immunity"},{"key":"35_CR37","doi-asserted-by":"publisher","first-page":"E2116","DOI":"10.1073\/pnas.1307185110","volume":"110","author":"T Yamaguchi","year":"2013","unstructured":"Yamaguchi, T. et al. Construction of self-recognizing regulatory T cells from conventional T cells by controlling CTLA-4 and IL-2 expression. Proc. Natl Acad. Sci. USA 110, E2116\u2013E2125 (2013).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"35_CR38","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/S1074-7613(00)80089-8","volume":"11","author":"H Nishimura","year":"1999","unstructured":"Nishimura, H., Nose, M., Hiai, H., Minato, N. & Honjo, T. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity 11, 141\u2013151 (1999).","journal-title":"Immunity"},{"key":"35_CR39","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1126\/science.291.5502.319","volume":"291","author":"H Nishimura","year":"2001","unstructured":"Nishimura, H. et al. Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science 291, 319\u2013322 (2001).","journal-title":"Science"},{"key":"35_CR40","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1038\/nm955","volume":"9","author":"T Okazaki","year":"2003","unstructured":"Okazaki, T. et al. Autoantibodies against cardiac troponin I are responsible for dilated cardiomyopathy in PD-1-deficient mice. Nat. Med. 9, 1477\u20131483 (2003).","journal-title":"Nat. Med."},{"key":"35_CR41","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1084\/jem.20022119","volume":"198","author":"AD Salama","year":"2003","unstructured":"Salama, A. D. et al. Critical role of the programmed death-1 (PD-1) pathway in regulation of experimental autoimmune encephalomyelitis. J. Exp. Med. 198, 71\u201378 (2003).","journal-title":"J. Exp. Med."},{"key":"35_CR42","doi-asserted-by":"publisher","first-page":"10691","DOI":"10.1073\/pnas.0307252101","volume":"101","author":"YE Latchman","year":"2004","unstructured":"Latchman, Y. E. et al. PD-L1-deficient mice show that PD-L1 on T cells, antigen-presenting cells, and host tissues negatively regulates T cells. Proc. Natl Acad. Sci. USA 101, 10691\u201310696 (2004).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"35_CR43","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/1074-7613(95)90125-6","volume":"3","author":"EA Tivol","year":"1995","unstructured":"Tivol, E. A. et al. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 3, 541\u2013547 (1995).","journal-title":"Immunity"},{"key":"35_CR44","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1126\/science.270.5238.985","volume":"270","author":"P Waterhouse","year":"1995","unstructured":"Waterhouse, P. et al. Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science 270, 985\u2013988 (1995).","journal-title":"Science"},{"key":"35_CR45","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1084\/jem.20141030","volume":"212","author":"AM Paterson","year":"2015","unstructured":"Paterson, A. M. et al. Deletion of CTLA-4 on regulatory T cells during adulthood leads to resistance to autoimmunity. J. Exp. Med. 212, 1603\u20131621 (2015).","journal-title":"J. Exp. Med."},{"key":"35_CR46","doi-asserted-by":"publisher","first-page":"E2383","DOI":"10.1073\/pnas.1603892113","volume":"113","author":"K Klocke","year":"2016","unstructured":"Klocke, K., Sakaguchi, S., Holmdahl, R. & Wing, K. Induction of autoimmune disease by deletion of CTLA-4 in mice in adulthood. Proc. Natl Acad. Sci. USA 113, E2383\u2013E2392 (2016).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"35_CR47","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1038\/ng1020","volume":"32","author":"L Prokunina","year":"2002","unstructured":"Prokunina, L. et al. A regulatory polymorphism in PDCD1 is associated with susceptibility to systemic lupus erythematosus in humans. Nat. Genet. 32, 666\u2013669 (2002).","journal-title":"Nat. Genet."},{"key":"35_CR48","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1093\/rheumatology\/ker211","volume":"50","author":"CH Huang","year":"2011","unstructured":"Huang, C. H. et al. Effects of genetic polymorphisms of programmed cell death 1 and its ligands on the development of ankylosing spondylitis. Rheumatology (Oxford) 50, 1809\u20131813 (2011).","journal-title":"Rheumatology (Oxford)"},{"key":"35_CR49","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1038\/sj.ejhg.5201214","volume":"12","author":"M Barreto","year":"2004","unstructured":"Barreto, M. et al. Evidence for CTLA4 as a susceptibility gene for systemic lupus erythematosus. Eur. J. Hum. Genet. 12, 620\u2013626 (2004).","journal-title":"Eur. J. Hum. Genet."},{"key":"35_CR50","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1038\/nature01621","volume":"423","author":"H Ueda","year":"2003","unstructured":"Ueda, H. et al. Association of the T cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature 423, 506\u2013511 (2003).","journal-title":"Nature"},{"key":"35_CR51","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1093\/rheumatology\/41.2.180","volume":"41","author":"B Vaidya","year":"2002","unstructured":"Vaidya, B. et al. An association between the CTLA4 exon 1 polymorphism and early rheumatoid arthritis with autoimmune endocrinopathies. Rheumatology (Oxford) 41, 180\u2013183 (2002).","journal-title":"Rheumatology (Oxford)"},{"key":"35_CR52","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1182\/blood-2008-12-195792","volume":"114","author":"M Ahmadzadeh","year":"2009","unstructured":"Ahmadzadeh, M. et al. Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood 114, 1537\u20131544 (2009).","journal-title":"Blood"},{"key":"35_CR53","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1038\/nm730","volume":"8","author":"H Dong","year":"2002","unstructured":"Dong, H. et al. Tumor-associated B7-H1 promotes T cell apoptosis: a potential mechanism of immune evasion. Nat. Med. 8, 793\u2013800 (2002).","journal-title":"Nat. Med."},{"key":"35_CR54","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1038\/nm863","volume":"9","author":"TJ Curiel","year":"2003","unstructured":"Curiel, T. J. et al. Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat. Med. 9, 562\u2013567 (2003).","journal-title":"Nat. Med."},{"key":"35_CR55","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1084\/jem.20082173","volume":"206","author":"DM Kuang","year":"2009","unstructured":"Kuang, D. M. et al. Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1. J. Exp. Med. 206, 1327\u20131337 (2009).","journal-title":"J. Exp. Med."},{"key":"35_CR56","doi-asserted-by":"publisher","first-page":"5552","DOI":"10.4049\/jimmunol.178.9.5552","volume":"178","author":"MR Nazareth","year":"2007","unstructured":"Nazareth, M. R. et al. Characterization of human lung tumor-associated fibroblasts and their ability to modulate the activation of tumor-associated T cells. J. Immunol. 178, 5552\u20135562 (2007).","journal-title":"J. Immunol."},{"key":"35_CR57","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1002\/hep.26694","volume":"59","author":"Y Han","year":"2014","unstructured":"Han, Y. et al. Human CD14+ CTLA-4+ regulatory dendritic cells suppress T cell response by cytotoxic T-lymphocyte antigen-4-dependent IL-10 and indoleamine-2,3-dioxygenase production in hepatocellular carcinoma. Hepatology 59, 567\u2013579 (2014).","journal-title":"Hepatology"},{"key":"35_CR58","doi-asserted-by":"publisher","first-page":"14987","DOI":"10.1073\/pnas.0806075105","volume":"105","author":"CI Liakou","year":"2008","unstructured":"Liakou, C. I. et al. CTLA-4 blockade increases IFNgamma-producing CD4+ ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients. Proc. Natl Acad. Sci. USA 105, 14987\u201314992 (2008).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"35_CR59","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1003466","volume":"363","author":"FS Hodi","year":"2010","unstructured":"Hodi, F. S. et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711\u2013723 (2010).","journal-title":"N. Engl. J. Med."},{"key":"35_CR60","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1016\/S1470-2045(16)30366-7","volume":"17","author":"FS Hodi","year":"2016","unstructured":"Hodi, F. S. et al. Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial. Lancet Oncol. 17, 1558\u20131568 (2016).","journal-title":"Lancet Oncol."},{"key":"35_CR61","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.1200\/JCO.2014.58.3708","volume":"33","author":"SN Gettinger","year":"2015","unstructured":"Gettinger, S. N. et al. Overall survival and long-term safety of nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer. J. Clin. Oncol. 33, 2004\u20132012 (2015).","journal-title":"J. Clin. Oncol."},{"key":"35_CR62","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/nature14011","volume":"515","author":"RS Herbst","year":"2014","unstructured":"Herbst, R. S. et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515, 563\u2013567 (2014).","journal-title":"Nature"},{"key":"35_CR63","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","volume":"372","author":"EB Garon","year":"2015","unstructured":"Garon, E. B. et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N. Engl. J. Med. 372, 2018\u20132028 (2015).","journal-title":"N. Engl. J. Med."},{"key":"35_CR64","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1056\/NEJMoa1412082","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert, C. et al. Nivolumab in previously untreated melanoma without BRAF mutation. N. Engl. J. Med. 372, 320\u2013330 (2015).","journal-title":"N. Engl. J. Med."},{"key":"35_CR65","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert, C. et al. Pembrolizumab versus ipilimumab in advanced melanoma. N. Engl. J. Med. 372, 2521\u20132532 (2015).","journal-title":"N. Engl. J. Med."},{"key":"35_CR66","doi-asserted-by":"publisher","first-page":"3158","DOI":"10.1158\/1078-0432.CCR-16-1761","volume":"23","author":"JH Yearley","year":"2017","unstructured":"Yearley, J. H. et al. PD-L2 expression in human tumors: relevance to anti-PD-1 therapy in cancer. Clin. Cancer Res. 23, 3158\u20133167 (2017).","journal-title":"Clin. Cancer Res."},{"key":"35_CR67","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1126\/science.271.5256.1734","volume":"271","author":"DR Leach","year":"1996","unstructured":"Leach, D. R., Krummel, M. F. & Allison, J. P. Enhancement of antitumor immunity by CTLA-4 blockade. Science 271, 1734\u20131736 (1996).","journal-title":"Science"},{"key":"35_CR68","doi-asserted-by":"publisher","first-page":"8099","DOI":"10.1073\/pnas.94.15.8099","volume":"94","author":"ED Kwon","year":"1997","unstructured":"Kwon, E. D. et al. Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer. Proc. Natl Acad. Sci. USA 94, 8099\u20138103 (1997).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"35_CR69","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/S1074-7613(00)80123-5","volume":"11","author":"P Shrikant","year":"1999","unstructured":"Shrikant, P., Khoruts, A. & Mescher, M. F. CTLA-4 blockade reverses CD8+ T cell tolerance to tumor by a CD4+ T cell- and IL-2-dependent mechanism. Immunity 11, 483\u2013493 (1999).","journal-title":"Immunity"},{"key":"35_CR70","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1084\/jem.20091918","volume":"207","author":"SA Quezada","year":"2010","unstructured":"Quezada, S. A. et al. Tumor-reactive CD4+ T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts. J. Exp. Med. 207, 637\u2013650 (2010).","journal-title":"J. Exp. Med."},{"key":"35_CR71","doi-asserted-by":"publisher","unstructured":"Perazella, M. & Shirali, A. Nephrotoxicity of cancer immunotherapies: past, present and future. J. Am. Soc. Nephrol. https:\/\/doi.org\/10.1681\/ASN.2018050488 (2018).","DOI":"10.1681\/ASN.2018050488"},{"key":"35_CR72","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1093\/ndt\/gfw467","volume":"32","author":"H Izzedine","year":"2017","unstructured":"Izzedine, H. et al. Renal effects of immune checkpoint inhibitors. Nephrol. Dial. Transplant. 32, 936\u2013942 (2017).","journal-title":"Nephrol. Dial. Transplant."},{"key":"35_CR73","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1016\/j.kint.2016.04.008","volume":"90","author":"FB Cortazar","year":"2016","unstructured":"Cortazar, F. B. et al. Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors. Kidney Int. 90, 638\u2013647 (2016).","journal-title":"Kidney Int."},{"key":"35_CR74","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1053\/j.ajkd.2016.02.057","volume":"68","author":"AC Shirali","year":"2016","unstructured":"Shirali, A. C., Perazella, M. A. & Gettinger, S. Association of acute interstitial nephritis with programmed cell death 1 inhibitor therapy in lung cancer patients. Am. J. Kidney Dis. 68, 287\u2013291 (2016).","journal-title":"Am. J. Kidney Dis."},{"key":"35_CR75","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1007\/s10637-014-0092-7","volume":"32","author":"H Izzedine","year":"2014","unstructured":"Izzedine, H. et al. Kidney injuries related to ipilimumab. Invest. New Drugs 32, 769\u2013773 (2014).","journal-title":"Invest. New Drugs"},{"key":"35_CR76","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1056\/NEJMc0904283","volume":"361","author":"F Fadel","year":"2009","unstructured":"Fadel, F., El Karoui, K. & Knebelmann, B. Anti-CTLA4 antibody-induced lupus nephritis. N. Engl. J. Med. 361, 211\u2013212 (2009).","journal-title":"N. Engl. J. Med."},{"key":"35_CR77","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1016\/j.kint.2015.11.028","volume":"89","author":"JM Kidd","year":"2016","unstructured":"Kidd, J. M. & Gizaw, A. B. Ipilimumab-associated minimal-change disease. Kidney Int. 89, 720 (2016).","journal-title":"Kidney Int."},{"key":"35_CR78","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1053\/j.ajkd.2017.04.026","volume":"70","author":"A Kitchlu","year":"2017","unstructured":"Kitchlu, A. et al. Nephrotic syndrome with cancer immunotherapies: a report of 2 cases. Am. J. Kidney Dis. 70, 581\u2013585 (2017).","journal-title":"Am. J. Kidney Dis."},{"key":"35_CR79","first-page":"1010A","volume":"27","author":"A Ray","year":"2016","unstructured":"Ray, A., Ghosh, S., Ghosh, M. & Yarlagadda, S. Nivolumab induced renal failure with collapsing focal segmental glomerulosclerosis (FSGS). J. Am. Soc. Nephrol. 27, 1010A (2016).","journal-title":"J. Am. Soc. Nephrol."},{"key":"35_CR80","first-page":"102A","volume":"27","author":"J Lin","year":"2016","unstructured":"Lin, J., Schiff, M., Salvatore, S., Shoustari, A. & Glezerman, I. Membranous nephropathy related to the checkpoint inhibitor nivolumab. J. Am. Soc. Nephrol. 27, 102A (2016).","journal-title":"J. Am. Soc. Nephrol."},{"key":"35_CR81","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1093\/ckj\/sfw024","volume":"9","author":"N Murakami","year":"2016","unstructured":"Murakami, N., Borges, T. J., Yamashita, M. & Riella, L. V. Severe acute interstitial nephritis after combination immune-checkpoint inhibitor therapy for metastatic melanoma. Clin. Kidney J. 9, 411\u2013417 (2016).","journal-title":"Clin. Kidney J."},{"key":"35_CR82","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1097\/CJI.0000000000000189","volume":"40","author":"RA Daanen","year":"2017","unstructured":"Daanen, R. A. et al. Nivolumab-associated nephrotic syndrome in a patient with renal cell carcinoma: a case report. J. Immunother. 40, 345\u2013348 (2017).","journal-title":"J. Immunother."},{"key":"35_CR83","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aal4922","volume":"9","author":"E Nolan","year":"2017","unstructured":"Nolan, E. et al. Combined immune checkpoint blockade as a therapeutic strategy for BRCA1-mutated breast cancer. Sci. Transl Med. 9, eaal4922 (2017).","journal-title":"Sci. Transl Med."},{"key":"35_CR84","doi-asserted-by":"publisher","first-page":"4876","DOI":"10.4049\/jimmunol.1200389","volume":"188","author":"ML Tarrio","year":"2012","unstructured":"Tarrio, M. L., Grabie, N., Bu, D. X., Sharpe, A. H. & Lichtman, A. H. PD-1 protects against inflammation and myocyte damage in T cell-mediated myocarditis. J. Immunol. 188, 4876\u20134884 (2012).","journal-title":"J. Immunol."},{"key":"35_CR85","doi-asserted-by":"publisher","first-page":"2513","DOI":"10.4049\/jimmunol.181.4.2513","volume":"181","author":"JA Lucas","year":"2008","unstructured":"Lucas, J. A. et al. Programmed death ligand 1 regulates a critical checkpoint for autoimmune myocarditis and pneumonitis in MRL mice. J. Immunol. 181, 2513\u20132521 (2008).","journal-title":"J. Immunol."},{"key":"35_CR86","doi-asserted-by":"publisher","first-page":"2062","DOI":"10.1161\/CIRCULATIONAHA.107.709360","volume":"116","author":"N Grabie","year":"2007","unstructured":"Grabie, N. et al. Endothelial programmed death-1 ligand 1 (PD-L1) regulates CD8+ T cell mediated injury in the heart. Circulation 116, 2062\u20132071 (2007).","journal-title":"Circulation"},{"key":"35_CR87","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","volume":"366","author":"JR Brahmer","year":"2012","unstructured":"Brahmer, J. R. et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 366, 2455\u20132465 (2012).","journal-title":"N. Engl. J. Med."},{"key":"35_CR88","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1056\/NEJMoa1611299","volume":"375","author":"AM Eggermont","year":"2016","unstructured":"Eggermont, A. M. et al. Prolonged survival in stage iii melanoma with ipilimumab adjuvant therapy. N. Engl. J. Med. 375, 1845\u20131855 (2016).","journal-title":"N. Engl. J. Med."},{"key":"35_CR89","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","volume":"375","author":"DB Johnson","year":"2016","unstructured":"Johnson, D. B. et al. Fulminant myocarditis with combination immune checkpoint blockade. N. Engl. J. Med. 375, 1749\u20131755 (2016).","journal-title":"N. Engl. J. Med."},{"key":"35_CR90","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/S0140-6736(18)30533-6","volume":"391","author":"JJ Moslehi","year":"2018","unstructured":"Moslehi, J. J., Salem, J.-E., Sosman, J. A., Lebrun-Vignes, B. & Johnson, D. B. Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis. Lancet 391, 933 (2018).","journal-title":"Lancet"},{"key":"35_CR91","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1016\/j.jacc.2018.02.037","volume":"71","author":"SS Mahmood","year":"2018","unstructured":"Mahmood, S. S. et al. Myocarditis in patients treated with immune checkpoint inhibitors. J. Am. Coll. Cardiol. 71, 1755\u20131764 (2018).","journal-title":"J. Am. Coll. Cardiol."},{"key":"35_CR92","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2016-216228","author":"R Gibson","year":"2016","unstructured":"Gibson, R., Delaune, J., Szady, A. & Markham, M. Suspected autoimmune myocarditis and cardiac conduction abnormalities with nivolumab therapy for non-small cell lung cancer. BMJ Case Rep. https:\/\/doi.org\/10.1136\/bcr-2016-216228 (2016).","journal-title":"BMJ Case Rep."},{"key":"35_CR93","first-page":"794842","volume":"2015","author":"S Yun","year":"2015","unstructured":"Yun, S., Vincelette, N. D., Mansour, I., Hariri, D. & Motamed, S. Late onset ipilimumab-induced pericarditis and pericardial effusion: a rare but life threatening complication. Case Rep. Oncol. Med. 2015, 794842 (2015).","journal-title":"Case Rep. Oncol. Med."},{"key":"35_CR94","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1177\/1078155216635853","volume":"23","author":"CA Dasanu","year":"2017","unstructured":"Dasanu, C. A., Jen, T. & Skulski, R. Late-onset pericardial tamponade, bilateral pleural effusions and recurrent immune monoarthritis induced by ipilimumab use for metastatic melanoma. J. Oncol. Pharm. Pract. 23, 231\u2013234 (2017).","journal-title":"J. Oncol. Pharm. Pract."},{"key":"35_CR95","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s40425-015-0048-2","volume":"3","author":"BP Geisler","year":"2015","unstructured":"Geisler, B. P., Raad, R. A., Esaian, D., Sharon, E. & Schwartz, D. R. Apical ballooning and cardiomyopathy in a melanoma patient treated with ipilimumab: a case of takotsubo-like syndrome. J. Immunother. Cancer 3, 4 (2015).","journal-title":"J. Immunother. Cancer"},{"key":"35_CR96","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s40425-016-0152-y","volume":"4","author":"L Heinzerling","year":"2016","unstructured":"Heinzerling, L. et al. Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy. J. Immunother. Cancer 4, 50 (2016).","journal-title":"J. Immunother. Cancer"},{"key":"35_CR97","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s40425-017-0296-4","volume":"5","author":"TG Norwood","year":"2017","unstructured":"Norwood, T. G. et al. Smoldering myocarditis following immune checkpoint blockade. J. Immunother. Cancer 5, 91 (2017).","journal-title":"J. Immunother. Cancer"},{"key":"35_CR98","doi-asserted-by":"publisher","DOI":"10.1007\/s12350-018-1293-9","author":"AI Loffler","year":"2018","unstructured":"Loffler, A. I. & Salerno, M. Cardiac MRI for the evaluation of oncologic cardiotoxicity. J. Nucl. Cardiol. https:\/\/doi.org\/10.1007\/s12350-018-1293-9 (2018).","journal-title":"J. Nucl. Cardiol."},{"key":"35_CR99","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1016\/j.jacc.2009.02.007","volume":"53","author":"MG Friedrich","year":"2009","unstructured":"Friedrich, M. G. et al. Cardiovascular magnetic resonance in myocarditis: a JACC White Paper. J. Am. Coll. Cardiol. 53, 1475\u20131487 (2009).","journal-title":"J. Am. Coll. Cardiol."},{"key":"35_CR100","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s11886-017-0835-0","volume":"19","author":"DY Wang","year":"2017","unstructured":"Wang, D. Y., Okoye, G. D., Neilan, T. G., Johnson, D. B. & Moslehi, J. J. Cardiovascular toxicities associated with cancer immunotherapies. Curr. Cardiol. Rep. 19, 21 (2017).","journal-title":"Curr. Cardiol. Rep."},{"key":"35_CR101","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1093\/annonc\/mdx286","volume":"28","author":"L Khoja","year":"2017","unstructured":"Khoja, L., Day, D., Wei-Wu Chen, T., Siu, L. L. & Hansen, A. R. Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review. Ann. Oncol. 28, 2377\u20132385 (2017).","journal-title":"Ann. Oncol."},{"key":"35_CR102","doi-asserted-by":"publisher","first-page":"230ra45","DOI":"10.1126\/scitranslmed.3008002","volume":"6","author":"S Iwama","year":"2014","unstructured":"Iwama, S. et al. Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody. Sci. Transl Med. 6, 230ra45 (2014).","journal-title":"Sci. Transl Med."},{"key":"35_CR103","doi-asserted-by":"publisher","first-page":"3225","DOI":"10.1016\/j.ajpath.2016.08.020","volume":"186","author":"P Caturegli","year":"2016","unstructured":"Caturegli, P. et al. Hypophysitis secondary to cytotoxic T-lymphocyte-associated protein 4 blockade: insights into pathogenesis from an autopsy series. Am. J. Pathol. 186, 3225\u20133235 (2016).","journal-title":"Am. J. Pathol."},{"key":"35_CR104","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.clim.2005.01.005","volume":"115","author":"H Ding","year":"2005","unstructured":"Ding, H., Wu, X. & Gao, W. PD-L1 is expressed by human renal tubular epithelial cells and suppresses T cell cytokine synthesis. Clin. Immunol. 115, 184\u2013191 (2005).","journal-title":"Clin. Immunol."},{"key":"35_CR105","doi-asserted-by":"publisher","first-page":"2919","DOI":"10.1681\/ASN.2006050418","volume":"17","author":"Z Spanou","year":"2006","unstructured":"Spanou, Z. et al. Involvement of drug-specific T cells in acute drug-induced interstitial nephritis. J. Am. Soc. Nephrol. 17, 2919\u20132927 (2006).","journal-title":"J. Am. Soc. Nephrol."},{"key":"35_CR106","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s40425-015-0081-1","volume":"3","author":"AA Tarhini","year":"2015","unstructured":"Tarhini, A. A. et al. Baseline circulating IL-17 predicts toxicity while TGF-beta1 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma. J. Immunother. Cancer 3, 39 (2015).","journal-title":"J. Immunother. Cancer"},{"key":"35_CR107","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1002\/ibd.20894","volume":"15","author":"C Abraham","year":"2009","unstructured":"Abraham, C. & Cho, J. Interleukin-23\/Th17 pathways and inflammatory bowel disease. Inflamm. Bowel Dis. 15, 1090\u20131100 (2009).","journal-title":"Inflamm. Bowel Dis."},{"key":"35_CR108","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1038\/nrneph.2017.112","volume":"13","author":"CF Krebs","year":"2017","unstructured":"Krebs, C. F. et al. T helper type 17 cells in immune-mediated glomerular disease. Nat. Rev. Nephrol. 13, 647\u2013659 (2017).","journal-title":"Nat. Rev. Nephrol."},{"key":"35_CR109","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1093\/annonc\/mdw640","volume":"28","author":"JC Osorio","year":"2017","unstructured":"Osorio, J. C. et al. Antibody-mediated thyroid dysfunction during T cell checkpoint blockade in patients with non-small-cell lung cancer. Ann. Oncol. 28, 583\u2013589 (2017).","journal-title":"Ann. Oncol."},{"key":"35_CR110","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s13075-017-1258-4","volume":"19","author":"H Shi","year":"2017","unstructured":"Shi, H. et al. Elevated serum autoantibodies against co-inhibitory PD-1 facilitate T cell proliferation and correlate with disease activity in new-onset systemic lupus erythematosus patients. Arthritis Res. Ther. 19, 52 (2017).","journal-title":"Arthritis Res. Ther."},{"key":"35_CR111","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1172\/JCI96798","volume":"128","author":"R Das","year":"2018","unstructured":"Das, R. et al. Early B cell changes predict autoimmunity following combination immune checkpoint blockade. J. Clin. Invest. 128, 715\u2013720 (2018).","journal-title":"J. Clin. Invest."},{"key":"35_CR112","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1038\/bjc.2016.358","volume":"115","author":"J Belliere","year":"2016","unstructured":"Belliere, J. et al. Acute interstitial nephritis related to immune checkpoint inhibitors. Br. J. Cancer 115, 1457\u20131461 (2016).","journal-title":"Br. J. Cancer"},{"key":"35_CR113","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1186\/s12882-016-0408-2","volume":"17","author":"K Jung","year":"2016","unstructured":"Jung, K., Zeng, X. & Bilusic, M. Nivolumab-associated acute glomerulonephritis: a case report and literature review. BMC Nephrol. 17, 188 (2016).","journal-title":"BMC Nephrol."},{"key":"35_CR114","first-page":"4607","volume":"32","author":"PM Forde","year":"2012","unstructured":"Forde, P. M., Rock, K., Wilson, G. & O\u2019Byrne, K. J. Ipilimumab-induced immune-related renal failure \u2014 a case report. Anticancer Res. 32, 4607\u20134608 (2012).","journal-title":"Anticancer Res."},{"key":"35_CR115","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s40425-017-0261-2","volume":"5","author":"L Bottlaender","year":"2017","unstructured":"Bottlaender, L. et al. Acute interstitial nephritis after sequential ipilumumab \u2014 nivolumab therapy of metastatic melanoma. J. Immunother. Cancer 5, 57 (2017).","journal-title":"J. Immunother. Cancer"},{"key":"35_CR116","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s40425-016-0205-2","volume":"5","author":"J Escandon","year":"2017","unstructured":"Escandon, J. et al. Interstitial nephritis in melanoma patients secondary to PD-1 checkpoint inhibitor. J. Immunother. Cancer 5, 3 (2017).","journal-title":"J. Immunother. Cancer"},{"key":"35_CR117","doi-asserted-by":"publisher","first-page":"e84","DOI":"10.1097\/MJT.0b013e3182a32ddc","volume":"22","author":"B Thajudeen","year":"2015","unstructured":"Thajudeen, B., Madhrira, M., Bracamonte, E. & Cranmer, L. D. Ipilimumab granulomatous interstitial nephritis. Am. J. Ther. 22, e84\u2013e87 (2015).","journal-title":"Am. J. Ther."},{"key":"35_CR118","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s40425-015-0057-1","volume":"3","author":"H Laubli","year":"2015","unstructured":"Laubli, H. et al. Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma. J. Immunother. Cancer 3, 11 (2015).","journal-title":"J. Immunother. Cancer"}],"container-title":["Nature Reviews Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41581-018-0035-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41581-018-0035-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41581-018-0035-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,5]],"date-time":"2025-07-05T20:53:37Z","timestamp":1751748817000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41581-018-0035-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,16]]},"references-count":118,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["35"],"URL":"https:\/\/doi.org\/10.1038\/s41581-018-0035-1","relation":{},"ISSN":["1759-5061","1759-507X"],"issn-type":[{"value":"1759-5061","type":"print"},{"value":"1759-507X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,16]]},"assertion":[{"value":"16 July 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}